Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Total Liabilities (2021 - 2025)

Historic Total Liabilities for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $1.6 million.

  • InMed Pharmaceuticals' Total Liabilities fell 3087.55% to $1.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6 million, marking a year-over-year decrease of 3087.55%. This contributed to the annual value of $2.1 million for FY2025, which is 1800.48% down from last year.
  • As of Q4 2025, InMed Pharmaceuticals' Total Liabilities stood at $1.6 million, which was down 3087.55% from $1.8 million recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Total Liabilities ranged from a high of $5.2 million in Q4 2021 and a low of $1.3 million during Q3 2023
  • For the 5-year period, InMed Pharmaceuticals' Total Liabilities averaged around $2.6 million, with its median value being $2.3 million (2024).
  • As far as peak fluctuations go, InMed Pharmaceuticals' Total Liabilities skyrocketed by 6985.2% in 2022, and later crashed by 6255.3% in 2023.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Total Liabilities stood at $5.2 million in 2021, then tumbled by 50.45% to $2.6 million in 2022, then decreased by 3.92% to $2.5 million in 2023, then dropped by 6.57% to $2.3 million in 2024, then tumbled by 30.88% to $1.6 million in 2025.
  • Its Total Liabilities was $1.6 million in Q4 2025, compared to $1.8 million in Q3 2025 and $2.1 million in Q2 2025.